Table 2

 Mean efficacy variables at baseline and the mean change after 24 weeks with the 95% confidence interval for the difference in change between the treatment groups

VariablePlacebo (n = 15)Leflunomide (n = 30)95% CI*p Value
BaselineMean changeBaselineMean change
*95% confidence interval for difference of mean change between placebo and leflunomide.
†General wellbeing of the patient according to physician.
BASDAI, Bath ankylosing spondylitis disease activity index; BASFI, Bath ankylosing spondylitis functional index; BASG, Bath ankylosing spondylitis global score; BASMI, Bath ankylosing spondylitis metrology index; ESR, erythrocyte sedimentation rate; SJC, swollen joint count.
BASG last week (0–10)5.8−0.66.9−1.3(−0.9 to 2.4)0.32
BASG last six months6.7−1.57.4−0.7(−2.2 to 0.6)0.26
Pain (0–10)6.2−0.56.8−1.4(−0.9 to 2.8)0.28
BASFI (0–10)5.4−−1.3 to 0.5)0.35
BASDAI (0–10)5.9−0.36.4−1.1(−0.5 to 2.0)0.20
BASMI (0–10)−0.1 to 0.8)0.10
SJC (0–44)0.4−−0.9 to 0.1)0.09
Global physician (0–10)†5.1−0.75.5−0.5(−1.1 to 0.8)0.70
ESR (mm/h)18.1−1.922.18.4(−17.8 to −2.9)0.002
C reactive protein (mg/l)21.4−−30.9 to 5.8)0.09